Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2015 16:15 ET | Source: Achaogen, Inc.

Achaogen Announces Appointment of Greg Stea to Board of Directors and Results of Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., June 11, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
May 11, 2015 16:20 ET | Source: Achaogen, Inc.

Achaogen Provides Clinical Update and First Quarter 2015 Results

SOUTH SAN FRANCISCO, May 11, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR)...
May 05, 2015 16:20 ET | Source: Achaogen, Inc.

Achaogen to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
April 30, 2015 05:30 ET | Source: Achaogen, Inc.

Achaogen to Receive $7.1 Million in Settlement of Claim With Defense Threat Reduction Agency (DTRA)

SOUTH SAN FRANCISCO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
April 09, 2015 05:30 ET | Source: Achaogen, Inc.

Achaogen to Present at 14th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
March 30, 2015 16:15 ET | Source: Achaogen, Inc.

Achaogen Announces Webcast Providing Update on Development Plan for Plazomicin

SOUTH SAN FRANCISCO, Calif., March 30, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
March 16, 2015 16:20 ET | Source: Achaogen, Inc.

Achaogen Announces Fourth Quarter and Full Year 2014 Results

SOUTH SAN FRANCISCO, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
March 12, 2015 16:30 ET | Source: Achaogen, Inc.

Achaogen to Present at the Jefferies 2015 Antibiotic Summit on March 18, 2015

SOUTH SAN FRANCISCO, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
March 12, 2015 16:15 ET | Source: Achaogen, Inc.

Achaogen Announces Appointment of Kent Lieginger and Alan Colowick to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
February 25, 2015 05:30 ET | Source: Achaogen, Inc.

Achaogen to Present at the Cowen and Company 35th Annual Health Care Conference on March 3, 2015

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...